Phase I clinical trial of recombinant prostate specific membrane antigen (rPSMA)-loaded mature autologous dendritic cells (CapPVax) [prostate cancer vaccine; Northwest Biotherapeutics] for the treatment of metastatic hormone refractory prostate cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 07 Aug 2013 Biomarkers information updated
- 10 Nov 2005 New trial record.